z-logo
open-access-imgOpen Access
Molecular and immunological rationale for the use of tyrosine kinase inhibitors and immune checkpoint inhibitors in glioblastomas
Author(s) -
Dal Bo Michele,
Baboci Lorena,
Toffoli Giuseppe
Publication year - 2019
Publication title -
journal of molecular and clinical medicine
Language(s) - English
Resource type - Journals
eISSN - 2617-5282
pISSN - 2616-3632
DOI - 10.31083/j.jmcm.2019.04.4201
Subject(s) - cancer research , tumor microenvironment , immune system , stromal cell , bevacizumab , tyrosine kinase , medicine , receptor tyrosine kinase , epidermal growth factor receptor , growth factor receptor , biology , cancer , immunology , chemotherapy , receptor

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom